+129.8%
AXON vs MRNA
+27.0%
+102.9%
-60.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.1% | -3.4% | +0.3% | -2.9% |
| 7D | -3.3% | -10.1% | +6.7% | -2.9% |
| 30D | -17.8% | +126.7% | -144.6% | -23.0% |
| 3M | +8.3% | +184.1% | -175.8% | +0.2% |
| 6M | -12.4% | +143.3% | -155.6% | -18.2% |
| YTD | -13.7% | +359.9% | -373.6% | -22.4% |
| 1Y | -33.1% | +454.2% | -487.2% | -40.3% |
| All | +129.8% | +27.0% | +102.9% | +100.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling